News
TRAW
6.68
-8.87%
-0.65
Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket
Benzinga · 1d ago
Weekly Report: what happened at TRAW last week (0106-0110)?
Weekly Report · 1d ago
Traws stock rallies 24% on avian flu drug update
Seeking Alpha · 4d ago
Expert Systems Announced Milestone in Traws Pharma's H5N1 Program; Tivoxavir Marboxil Shows Broad-Spectrum Efficacy In Phase 1 Trial With No Adverse Events; Single Dose Maintains Plasma Levels Above EC90 For Over 23 Days
Benzinga · 4d ago
EXPERT SYSTEMS: WITH COMPLETION OF PHASE 1 TRIALS, PLANS ARE UNDERWAY TO INITIATE PHASE 2 EFFICACY STUDIES IN FIRST HALF OF 2025
Reuters · 4d ago
Weekly Report: what happened at TRAW last week (1230-0103)?
Weekly Report · 01/06 09:57
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 12/30/2024 21:05
Nasdaq Down Over 100 Points; US Pending Home Sales Increase In November
Benzinga · 12/30/2024 19:14
Traws stock plunges 43% on financing update
Seeking Alpha · 12/30/2024 18:16
Crude Oil Gains 1%; Chicago PMI Falls In December
Benzinga · 12/30/2024 17:55
US Stocks Open Lower; Dow Tumbles 600 Points
Benzinga · 12/30/2024 15:07
Traws Pharma Announces Financing By Investors - Quick Facts
NASDAQ · 12/30/2024 13:42
Traws Pharma announces $72.6M financing
TipRanks · 12/30/2024 13:30
Press Release: Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval
Dow Jones · 12/30/2024 13:00
Weekly Report: what happened at TRAW last week (1223-1227)?
Weekly Report · 12/30/2024 09:55
Traws Pharma Inc trading resumes
TipRanks · 12/27/2024 15:10
Traws Pharma Inc trading halted, volatility trading pause
TipRanks · 12/27/2024 15:05
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 12/24/2024 21:06
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 12/23/2024 21:07
Gold Moves Lower, Rumble Shares Jump
Benzinga · 12/23/2024 19:08
More
Webull provides a variety of real-time TRAW stock news. You can receive the latest news about Traws Pharma through multiple platforms. This information may help you make smarter investment decisions.
About TRAW
Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a Mpro protease inhibitor for COVID19. Narazaciclib is a cyclin-dependent kinases (CDK) 4/6 inhibitor for low-grade endometrioid endometrial cancer (LGEEC). Narazaciclib’s mechanism of action in LGEEC is validated by phase II studies with other approved CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib. Narazaciclib is in phase I/IIa study to define the Phase II dose (RP2D).